VANCOUVER, British Columbia, May 26, 2015 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox’s President & CEO, will present a corporate overview at the upcoming 2015 Jefferies Global Healthcare Conference on Wednesday, June 3rd at 8:30 AM Eastern Time.
A live audio webcast and archive of the event will be available at: http://wsw.com/webcast/jeff88/aqxp/
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast, as well as the corporate overview being presented, will be available on the Investor Relations page of Aquinox’s website at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox’s lead drug candidate, AQX- 1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Having successfully completed multiple preclinical studies and clinical trials with AQX-1225, Aquinox is now advancing through Phase 2 development. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.
| Investor Contact Info: | |
| Brendan Payne | |
| Senior Manager, Investor Relations | |
| Aquinox Pharmaceuticals, Inc. | |
| 604.629.9223 Ext. 109 | |
| ir@aqxpharma.com | |
| Communications Contact Info: | |
| Heather Savelle | |
| Vice President | |
| MacDougall Biomedical Communications | |
| 781.235.3060 | |
| aquinox@macbiocom.com | |
Help employers find you! Check out all the jobs and post your resume.
